EUVIMEDEUVIMED entdecken
Crossref

CRISPR-dCas9-Mediated PTEN Activation via Tumor Cell Membrane-Coated Nanoplatform Enhances Sensitivity to Tyrosine Kinase Inhibitors in Nonsmall Cell Lung Cancer

Kaiyong Yang, Chunli Zhang, Zeyu Wang, Qiqing Huang, Jing Qian, Gaoyu Shi, Wenwen Sun, Jinqiu Wang, Yu Ji, Zhaorui Sun, Yanni Song, Xin Han iD

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.4c21740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Kaiyong Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China. Hauptthemen laut MEDLINE: Tyrosine Kinase Inhibitors, PTEN Phosphohydrolase, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Graduate Research and Innovation Projects of Jiangsu Province, Major Project of Philosophy and Social Science Research in Colleges and Universities of Jiangsu Province, Harbin Medical University Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tyrosine Kinase InhibitorsPTEN PhosphohydrolaseCarcinoma, Non-Small-Cell LungLung NeoplasmsCRISPR-Cas SystemsErbB ReceptorsDrug Resistance, NeoplasmGefitinibAntineoplastic AgentsNanoparticle Drug Delivery SystemCell MembraneCRISPR-Associated Protein 9HumansAnimalsMiceCell Line, Tumor

Stichwörter der Autor:innen

CRISPR-dCas9-VPRFEGFR-mutated nonsmall cell lung cancerPTENdrug resistancesynergistic therapy

Substanzen

Tyrosine Kinase InhibitorsPTEN PhosphohydrolaseCRISPR-Associated Protein 9EGFR protein, humanErbB ReceptorsGefitinibAntineoplastic AgentsNanoparticle Drug Delivery System

Autor:innen und Institutionen

  • The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • Department of Emergency Medicine, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210002, China.
  • Department of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin 150081, China.

ORCID-Profile: Xin Han

Förderung

  • Graduate Research and Innovation Projects of Jiangsu Province
  • Major Project of Philosophy and Social Science Research in Colleges and Universities of Jiangsu Province
  • Harbin Medical University Cancer Hospital
  • National Natural Science Foundation of China
  • Jiangsu Key Discipline Construction Fund of the 14th Five-Year Plan
  • National Natural Science Foundation supporting project of Nanjing University of Chinese Medicine
  • Yangtze River Delta joint sci-tech innovation and research projects

Zitieren

APA

Yang, K., Zhang, C., Wang, Z., Huang, Q., Qian, J., Shi, G., Sun, W., Wang, J., Ji, Y., Sun, Z., Song, Y., & Han, X. (2025). CRISPR-dCas9-Mediated PTEN Activation via Tumor Cell Membrane-Coated Nanoplatform Enhances Sensitivity to Tyrosine Kinase Inhibitors in Nonsmall Cell Lung Cancer. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c21740

Vancouver

Yang K, Zhang C, Wang Z, Huang Q, Qian J, Shi G, et al. CRISPR-dCas9-Mediated PTEN Activation via Tumor Cell Membrane-Coated Nanoplatform Enhances Sensitivity to Tyrosine Kinase Inhibitors in Nonsmall Cell Lung Cancer. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c21740

BibTeX
@article{Yang2025,
  author = {Yang, Kaiyong and Zhang, Chunli and Wang, Zeyu and Huang, Qiqing and Qian, Jing and Shi, Gaoyu and Sun, Wenwen and Wang, Jinqiu and Ji, Yu and Sun, Zhaorui and Song, Yanni and Han, Xin},
  title = {CRISPR-dCas9-Mediated PTEN Activation via Tumor Cell Membrane-Coated Nanoplatform Enhances Sensitivity to Tyrosine Kinase Inhibitors in Nonsmall Cell Lung Cancer},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.4c21740}
}
Kostenlos starten →